News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,077 Results
Type
Article (13817)
Company Profile (101)
Press Release (252159)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88069)
Career Advice (465)
Deals (15345)
Drug Delivery (67)
Drug Development (36608)
Employer Resources (49)
FDA (6299)
Job Trends (6202)
News (150259)
Policy (14045)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23240)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (42)
Approvals (6339)
Artificial intelligence (113)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (645)
Cardiovascular disease (72)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (90)
Cervical cancer (4)
Clinical research (30947)
Collaboration (352)
Compensation (159)
Complete response letters (17)
COVID-19 (759)
CRISPR (22)
C-suite (128)
Cystic fibrosis (37)
Data (667)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1325)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32235)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37604)
Executive appointments (400)
FDA (6741)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (217)
Gene editing (40)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (23)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (35)
Indications (14)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5881)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (163)
MASH (34)
Medical device (1277)
Medtech (1279)
Mergers & acquisitions (9675)
Metabolic disorders (267)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (152)
Opinion (119)
Ovarian cancer (22)
Pain (54)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (30)
Peanut (10)
People (28988)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8055)
Phase II (13092)
Phase III (11749)
Pipeline (471)
Policy (72)
Postmarket research (1401)
Preclinical (3230)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2637)
Recruiting (17)
Regulatory (10141)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (38)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (32)
The Weekly (30)
Vaccines (157)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (12)
Last 7 days (283)
Last 30 days (860)
Last 365 days (11682)
2025 (3931)
2024 (12504)
2023 (14248)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20150)
Australia (2616)
California (1785)
Canada (932)
China (248)
Colorado (72)
Connecticut (70)
Delaware (61)
Europe (39524)
Florida (341)
Georgia (39)
Idaho (9)
Illinois (203)
India (16)
Indiana (137)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (13)
Louisiana (1)
Maine (2)
Maryland (264)
Massachusetts (1538)
Michigan (30)
Minnesota (96)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (787)
New Mexico (7)
New York (533)
North Carolina (404)
North Dakota (2)
Northern California (733)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (460)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (750)
Tennessee (34)
Texas (237)
United States (7467)
Utah (34)
Virginia (79)
Washington D.C. (31)
Washington State (124)
Wisconsin (17)
266,077 Results for "alora pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Acella Pharmaceuticals, LLC, an Alora Pharmaceuticals, LLC Subsidiary, Partners with Paloma Health for Hypothyroidism Patients
October 23, 2024
·
2 min read
Alora Pharmaceuticals, LLC announces the availability of Once-Daily Relexxii® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Alora Pharmaceuticals, LLC , the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii ® (methylphenidate hydrochloride extended-release tablets).
December 19, 2023
·
3 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc. today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora).
March 14, 2023
·
9 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced the closing of its divestment of DSUVIA® to Alora Pharmaceuticals.
April 5, 2023
·
6 min read
Deals
Alora Pharmaceuticals Celebrates Acquisition of Monarch Manufacturing Facility
Alora Pharmaceuticals, LLC, is pleased to announce that its wholly owned subsidiary, Sovereign Pharmaceuticals, LLC, has acquired, through bankruptcy proceedings, substantially all of Monarch PCM, LLC’s manufacturing capabilities located in Fort Worth, TX.
January 10, 2023
·
2 min read
FDA
Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announces the FDA approval and availability of DHIVY™ for the treatment of Parkinson’s disease
Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in November 2021.
February 14, 2022
·
3 min read
Deals
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US subsidiaries dedicated to the legacy business and its Marietta, Georgia, manufacturing facility, to Alora Pharmaceuticals, LLC, effective August 27, 2021.
August 30, 2021
·
5 min read
Pharm Country
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.
June 25, 2021
·
7 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 26,608
Next
